Combined targeting of MEK/MAPK and PI3K/Akt signalling in multiple myeloma
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Combined targeting of MEK/MAPK and PI3K/Akt signalling in multiple myeloma
Authors
Keywords
-
Journal
BRITISH JOURNAL OF HAEMATOLOGY
Volume 159, Issue 4, Pages 430-440
Publisher
Wiley
Online
2012-09-17
DOI
10.1111/bjh.12039
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer
- (2012) T. Shimizu et al. CLINICAL CANCER RESEARCH
- Optimal induction of myeloma cell death requires dual blockade of phosphoinositide 3-kinase and mTOR signalling and is determined by translocation subtype
- (2012) C Stengel et al. LEUKEMIA
- Cytokinetically quiescent (G0/G1) human multiple myeloma cells are susceptible to simultaneous inhibition of Chk1 and MEK1/2
- (2011) X.-Y. Pei et al. BLOOD
- Can multiple myeloma become a curable disease?
- (2011) J. F. San-Miguel et al. HAEMATOLOGICA
- Initial genome sequencing and analysis of multiple myeloma
- (2011) Michael A. Chapman et al. NATURE
- Multiple Myeloma
- (2011) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutated RAS and constitutively activated Akt delineate distinct oncogenic pathways, which independently contribute to multiple myeloma cell survival
- (2010) T. Steinbrunn et al. BLOOD
- A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression
- (2010) C. M. Annunziata et al. BLOOD
- Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo
- (2010) Kihyun Kim et al. BRITISH JOURNAL OF HAEMATOLOGY
- Response and determinants of cancer cell susceptibility to PI3K inhibitors: Combined targeting of PI3K and Mek1 as an effective anticancer strategy
- (2010) Ker Yu et al. CANCER BIOLOGY & THERAPY
- PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant Cancers
- (2009) S. Wee et al. CANCER RESEARCH
- In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models
- (2009) K. P. Hoeflich et al. CLINICAL CANCER RESEARCH
- Hotspot mutations of PIK3CA and AKT1 genes are absent in multiple myeloma
- (2009) Said I. Ismail et al. LEUKEMIA RESEARCH
- Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cells
- (2008) Y. Dai et al. BLOOD
- Combined functional and molecular analysis of tumor cell signaling defines 2 distinct myeloma subgroups: Akt-dependent and Akt-independent multiple myeloma
- (2008) A. Zollinger et al. BLOOD
- Multiple myeloma
- (2008) R. A. Kyle et al. BLOOD
- Bone marrow microenvironment and the identification of new targets for myeloma therapy
- (2008) K Podar et al. LEUKEMIA
- Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma
- (2008) T Stühmer et al. LEUKEMIA
- Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
- (2008) Jeffrey A Engelman et al. NATURE MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now